And so, another working week is about to come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to tidy up around the Pharmalot campus, catch up on some reading, and prep for the annual Woodstock-like gathering for biopharma enthusiasts next week. And what about you? In some locales, you may want to make sure your pipes are warm (no double entendre implied). You could calculate the impact of the tax bill. Or plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy and see you soon …

Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, Reuters tells us, citing a study in JAMA Internal Medicine. The proportion of U.S. adults prescribed gabapentinoids climbed from 1.2 percent in 2002 to 3.9 percent by 2015, a period that also saw a surge in opioid overdoses and deaths.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy